An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity
about
Analysis of human immunodeficiency virus type 1 Gag ubiquitinationAltering the tropism of lentiviral vectors through pseudotyping.Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cellsProteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2Toxin-based therapeutic approachesDynamics of HIV-1 assembly and releaseEnzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavirCumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 gag cause a late budding defect.Membrane-anchored peptide inhibits human immunodeficiency virus entry.Evidence that the Bacillus subtilis SpoIIGA protein is a novel type of signal-transducing aspartic proteaseExpression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccinesA simple fluorescence based assay for quantification of human immunodeficiency virus particle releaseInhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nefStructural analysis of HIV-1 maturation using cryo-electron tomography.Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity.Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virusViral evolution in response to the broad-based retroviral protease inhibitor TL-3.HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activityEffects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.Production, purification and titration of a lentivirus-based vector for gene delivery purposes.Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particlesMethods for gene transfer to the central nervous system.Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells.Kinetics of the dimerization of retroviral proteases: the "fireman's grip" and dimerization.Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integrationActive foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein.Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner.Inhibitors of Deubiquitinating Enzymes Block HIV-1 Replication and Augment the Presentation of Gag-Derived MHC-I Epitopes.Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity.The cellular protein lyric interacts with HIV-1 Gag.Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.Design of a trans protease lentiviral packaging system that produces high titer virus.Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association.Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis.Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.LentiPro26: novel stable cell lines for constitutive lentiviral vector production.
P2860
Q24531968-ED7B8A2B-433F-416B-B38C-04AD07C99B23Q24538987-CC4626A4-8B7E-4300-8C54-9D7B384DD88AQ24599011-D528D23A-1E18-4A80-B6EF-FD5E69A192D7Q24643016-9EE685AF-351E-4C90-A9D4-E8757A1A8DB7Q27013664-1EE27082-6F10-46E1-BDC7-F1C096895511Q27316126-D30D3743-4356-4654-9BC5-79E8EAD9060FQ27650863-656F4EF8-3D3E-4B91-BE40-BCD1A8EE7576Q27863926-9C609812-7FE4-46A4-961D-46A65B18D8F1Q28354004-D0816162-619F-4A13-916D-6C4ABD165D8AQ28489003-B4E99231-9293-4848-8BE2-ADA9C743C38BQ30332833-8BDCAEF4-B0D8-4116-91CC-F12B3457B32BQ33560406-C4F63C01-F0D2-4CB2-A731-C70E7BCB34C1Q33768829-EA538BCD-1AA5-43B2-9474-D21801E8EB31Q33769181-94BEBC8F-7BFF-4E09-B987-EC2168059A41Q33785282-A74939F4-C0FE-444D-98DB-224047545517Q33842020-AB98E72E-BF4E-4D8D-A2CF-5C281DA95D4EQ33846032-A054914B-70D2-4BDD-A82C-2C42F8E270ADQ33964165-770BC38D-C4D8-424E-8F16-8873C1248D52Q34033572-C5E98F28-F583-41CA-8AB1-8448DB65E707Q34534697-9047F0D3-19FA-4FFA-98DF-E3E34D4156A1Q35020604-9FCE681D-4DE3-42B3-B4A8-A784009B84B7Q35115071-1B775925-550F-4BD4-8596-33CB3E2DB156Q35860937-7D8493BE-259A-485F-A7D3-030D877AB721Q35902332-C8A7CEAC-7CBE-4BD1-8960-F81AF5C0151DQ36409179-26B11DCA-5B61-4644-9627-748CC2983635Q36631356-133D20EB-1019-49A4-8CE6-92053791001DQ36684330-5ED8E819-FDCF-4625-A0D3-BB686862F6D6Q38290008-09563F7B-22CD-400F-9C38-2F3E2D603FC4Q38316167-A0EBCC1F-7CEC-45AB-84D6-461F90DAC937Q38626145-A2F775AC-1045-4A44-A981-09EDB2656DCCQ39579012-DB5EE962-57BE-4665-8C63-158E907F258FQ39579642-6B5C4207-0CA9-4B65-8664-EAD7AF34365DQ39669187-B291250C-F1DC-46CA-9C0E-75AACB05D4E9Q39991984-C3BC33D6-71EC-44EB-A44B-A0D9A711E2C4Q40029687-447B1B7E-C40B-4E52-A07B-6BEE6E743B06Q40112050-E65793E5-8509-4C84-8CDD-84F8B72FCE98Q42068562-23D80E21-1660-4626-8C83-DBE57E37FEE2Q42994694-1DC5A5DB-85F7-4F6D-A59A-A9EEF07C9795Q54247043-31B32F9F-8E6B-4C37-A85E-8EBE14632B2D
P2860
An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
An active-site mutation in the ...... rus maturation and infectivity
@en
An active-site mutation in the human immunodeficiency virus type 1 proteinase
@nl
type
label
An active-site mutation in the ...... rus maturation and infectivity
@en
An active-site mutation in the human immunodeficiency virus type 1 proteinase
@nl
prefLabel
An active-site mutation in the ...... rus maturation and infectivity
@en
An active-site mutation in the human immunodeficiency virus type 1 proteinase
@nl
P2093
P2860
P1433
P1476
An active-site mutation in the ...... rus maturation and infectivity
@en
P2093
Kräusslich HG
Litterst MA
Rippmann F
P2860
P304
P407
P577
1995-11-01T00:00:00Z